2'-methoxykurarinone: cytotoxic lavandulyl flavanone from Sophora flavescens; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(2S)-2'-methoxykurarinone : A dimethoxyflavanone that is (2S)-(-)-kurarinone in which the hydroxy group at position 2' is replaced by a methoxy group. Isolated from the roots of Sophora flavescens, it exhibits cytotoxicity against human myeloid leukemia HL-60 cells. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Sophora | genus | A plant genus of the family FABACEAE.[MeSH] | Fabaceae | The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH] |
| Sophora flavescens | species | [no description available] | Fabaceae | The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 11982641 |
| CHEMBL ID | 496451 |
| CHEBI ID | 66151 |
| MeSH ID | M0366825 |
| Synonym |
|---|
| (2s)-7,4'-dihydroxy-8-lavandulyl-5,2'-dimethoxyflavanone |
| LMPK12140500 |
| (2s)-2'-methoxykurarinone |
| CHEMBL496451 , |
| chebi:66151 , |
| (2s)-2'-methoxy kurarinone |
| (2s)-7-hydroxy-2-(4-hydroxy-2-methoxyphenyl)-5-methoxy-8-[(2r)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydro-4h-chromen-4-one |
| 7,4'-dihydroxy-5,2'-dimethoxy-8-lavandulylflavanone |
| bdbm50377944 |
| 270249-38-2 |
| 2'-methoxykurarinone |
| 2'-o-methylkurarinone |
| kurarinone, 2'-o-methyl- |
| AKOS032962578 |
| Q27134673 |
| (2s)-7-hydroxy-2-(4-hydroxy-2-methoxyphenyl)-5-methoxy-8-[(2r)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one |
| HY-N1746 |
| CS-0017422 |
| MS-28230 |
| GLXC-14149 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| dimethoxyflavanone | A methoxyflavanone that is flavanone with two methoxy substituents. |
| dihydroxyflavanone | Any hydroxyflavanone carrying two hydroxy substituents. |
| 4'-hydroxyflavanones | Any hydroxyflavanone having a hydroxy substituent located at position 4'. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-secretase 1 | Homo sapiens (human) | IC50 (µMol) | 6.7000 | 0.0006 | 1.6194 | 10.0000 | AID344054 |
| Beta-secretase 1 | Homo sapiens (human) | Ki | 10.6000 | 0.0003 | 1.3524 | 8.0000 | AID344054 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| amyloid-beta binding | Beta-secretase 1 | Homo sapiens (human) |
| endopeptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| aspartic-type endopeptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| protein binding | Beta-secretase 1 | Homo sapiens (human) |
| peptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| beta-aspartyl-peptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| enzyme binding | Beta-secretase 1 | Homo sapiens (human) |
| protein serine/threonine kinase binding | Beta-secretase 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID344054 | Inhibition of human BACE1 | 2008 | Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14 | BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. |
| AID380063 | Cytotoxicity against human HL60 cells after 96 hrs by MTT assay | 2000 | Journal of natural products, May, Volume: 63, Issue:5 | Cytotoxic lavandulyl flavanones from Sophora flavescens. |
| AID344052 | Inhibition of human BACE1 expressed in HEK293 cells assessed as reduction in soluble APPalpha level after 4 hrs by Western blot analysis | 2008 | Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14 | BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. |
| AID344053 | Inhibition of human BACE1 expressed in HEK293 cells assessed as reduction in soluble APPbeta level after 4 hrs by Western blot analysis | 2008 | Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14 | BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.82) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||